Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Briquilimab - Jasper Therapeutics

Drug Profile

Briquilimab - Jasper Therapeutics

Alternative Names: AMG-191; JSP-191

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; National Heart, Lung and Blood Institute; Stanford University
  • Developer Amgen; AVROBIO; Jasper Therapeutics
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic urticaria
  • Phase I Myelodysplastic syndromes
  • Preclinical Fabry's disease; Gaucher's disease
  • Discontinued Inflammation

Most Recent Events

  • 10 Jan 2024 Jasper Therapeutics plans a phase Ib/IIa SPOTLIGHT trial for Chronic urticaria in European Union (SC) in first quarter of 2024
  • 05 Jan 2024 The European Medicines Agency (EMA) approves clinical trial applications (CTA) application for briquilimab in chronic urticaria
  • 30 Nov 2023 Phase-I/II clinical trials in Chronic-urticaria (Treatment-experienced) in European Union (SC) (NCT06162728)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top